BCOR and basal cell carcinoma: Thus Vismodegib (GDC-0449) [34] and Erismodegib (NVP-LDE225) [35], both FDA approved drugs for the treatment of the basal cell carcinoma, could became relevant in the treatment of CNS-HGNET-BCOR, possibly in combination with ATO.